- Home
- TLSI vs MCR Comparison
TLSI vs MCR Comparison
Compare TLSI & MCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSI | MCR |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 263.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TLSI | MCR |
|---|---|---|
| Price | $7.26 | $6.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | ★ 175.5K | 66.7K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $40,207,000.00 | N/A |
| Revenue This Year | $55.06 | N/A |
| Revenue Next Year | $46.04 | N/A |
| P/E Ratio | ★ N/A | $16.61 |
| Revenue Growth | ★ 49.52 | N/A |
| 52 Week Low | $3.42 | $5.63 |
| 52 Week High | $7.70 | $6.70 |
Technical Indicators
Market Signals| Indicator | TLSI | MCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.96 | 45.91 |
| Support Level | $6.06 | $6.30 |
| Resistance Level | $7.70 | $6.35 |
| Average True Range (ATR) | 0.58 | 0.05 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 81.08 | 36.75 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.